Compounds > pioglitazone
Page last updated: 2024-08-16

pioglitazone and farglitazar

pioglitazone has been researched along with farglitazar in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's7 (87.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Blanchard, SG; Brackeen, MF; Brown, KK; Cobb, JE; Collins, JL; Harrington, WW; Hashim, MA; Henke, BR; Hull-Ryde, EA; Kaldor, I; Kliewer, SA; Lake, DH; Leesnitzer, LM; Lehmann, JM; Lenhard, JM; Miller, JF; Mook, RA; Noble, SA; Oliver, W; Orband-Miller, LA; Parks, DJ; Plunket, KD; Szewczyk, JR; Willson, TM1
Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM1
Ayscue, AH; Henke, BR; Lambert, MH; Leesnitzer, LM; Liu, KG; Oliver, WR; Plunket, KD; Sternbach, DD; Willson, TM; Xu, HE1
Agostini, M; Chatterjee, VK; Garnes, KT; Gurnell, M; Levinson, SH; O'Rahilly, S; Rajanayagam, O; Savage, DB; Schwabe, JW; Smith, AG; Willson, TM; Wood, EM; Xu, HE1
Bonev, AD; Eckman, DM; Gomez, MF; Heppner, TJ; Nelson, MT; Petkov, GV1
Brown, KK; Carrick, KM; Chen, L; Clifton, LG; McNulty, JA; Pahel, GL; Stimpson, SA; Strum, JC; Winegar, DA; Yang, B1
Chen, J; Chen, Q; Jiang, H; Shen, J; Shen, X; Sun, T1
Ashton, TT; Baines, D; Bisi, J; Blazer-Yost, BL; Brown, KK; Harrington, W; Kalsi, K; Maurio, FP; Murray, D; Nofziger, C; Smith, CD; West, TA1

Reviews

1 review(s) available for pioglitazone and farglitazar

ArticleYear
The PPARs: from orphan receptors to drug discovery.
    Journal of medicinal chemistry, 2000, Feb-24, Volume: 43, Issue:4

    Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors

2000

Other Studies

7 other study(ies) available for pioglitazone and farglitazar

ArticleYear
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
    Journal of medicinal chemistry, 1998, Dec-03, Volume: 41, Issue:25

    Topics: Administration, Oral; Aminopyridines; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Lipids; Male; Mice; Oxazoles; Propionates; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Stereoisomerism; Structure-Activity Relationship; Transcription Factors; Transfection; Tyrosine

1998
Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight.
    Bioorganic & medicinal chemistry letters, 2001, Dec-17, Volume: 11, Issue:24

    Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Male; Molecular Weight; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Tyrosine

2001
Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.
    Endocrinology, 2004, Volume: 145, Issue:4

    Topics: Amino Acid Sequence; Cell Line; Gene Expression; Genes, Dominant; Humans; Leucine; Ligands; Methionine; Models, Structural; Molecular Sequence Data; Monocytes; Mutation; Oxazoles; Pioglitazone; Proline; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Transfection; Tyrosine; Valine

2004
Novel PPARgamma agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries.
    Pharmacology, 2005, Volume: 73, Issue:1

    Topics: Algorithms; Animals; Barium; Benzophenones; Blood Pressure; Calcium Channels; Electrophysiology; Female; Hypoglycemic Agents; In Vitro Techniques; Membrane Potentials; Mesenteric Arteries; Muscle Cells; Muscle Tonus; Muscle, Smooth, Vascular; Oxazoles; Patch-Clamp Techniques; Pioglitazone; PPAR gamma; Rats; Rats, Sprague-Dawley; Thiazolidinediones; Tyrosine; Vasodilation

2005
Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats.
    BMC pharmacology, 2004, Oct-18, Volume: 4

    Topics: Adiponectin; Animals; Biomarkers; Carrier Proteins; Diabetes Mellitus; Fatty Acid-Binding Proteins; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Lipids; Male; Obesity; Oxazoles; Pioglitazone; PPAR gamma; Rats; Rats, Sprague-Dawley; Rats, Zucker; Thiazolidinediones; Tyrosine

2004
A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist.
    Analytical biochemistry, 2004, Dec-15, Volume: 335, Issue:2

    Topics: alpha-Galactosidase; Anilides; Cells, Cultured; Chromans; CREB-Binding Protein; Drug Evaluation, Preclinical; Genes, Reporter; Indomethacin; Ligands; Nuclear Proteins; Oxazoles; Pioglitazone; PPAR gamma; Prostaglandin D2; Protein Binding; Rosiglitazone; Thiazolidinediones; Trans-Activators; Troglitazone; Two-Hybrid System Techniques; Tyrosine; Yeasts

2004
PPARgamma agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line.
    American journal of physiology. Renal physiology, 2009, Volume: 297, Issue:1

    Topics: Animals; Biological Transport; Cell Line; Chlorides; Cystic Fibrosis Transmembrane Conductance Regulator; Dogs; Dose-Response Relationship, Drug; Epithelial Sodium Channels; Kidney; Ligands; Models, Animal; Oxazoles; Pioglitazone; PPAR gamma; RNA, Messenger; Signal Transduction; Thiazolidinediones; Tyrosine; Vasopressins

2009